Zika Virus Infections-Pipeline Review, H2 2016

Zika Virus Infections-Pipeline Review, H2 2016


  • Products Id :- GMDHC8899IDB
  • |
  • Pages: 175
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Zika Virus Infections-Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Zika Virus Infections-Pipeline Review, H2 2016, provides an overview of the Zika Virus Infections (Infectious Disease) pipeline landscape.

Zika virus infection is caused by a virus transmitted primarily by Aedes mosquitoes. Zika virus is a member of the Flaviviridae family. Symptoms include fever, skin rashes, conjunctivitis, muscle and joint pain, malaise, and headache. Risk factors include being in tropical and subtropical areas. Zika virus can be transmitted through sexual intercourse. Treatment is aimed at relieving symptoms (joint pain and fever) with fluids and medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Zika Virus Infections-Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Zika Virus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Zika Virus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Zika Virus Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 1, 29 and 21 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 2, 5 and 4 molecules, respectively.

Zika Virus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Zika Virus Infections (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Zika Virus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Zika Virus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Zika Virus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Zika Virus Infections (Infectious Disease)

Reasons to Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Zika Virus Infections (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Zika Virus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Zika Virus Infections Overview 8

Therapeutics Development 9

Pipeline Products for Zika Virus Infections-Overview 9

Pipeline Products for Zika Virus Infections-Comparative Analysis 10

Zika Virus Infections-Therapeutics under Development by Companies 11

Zika Virus Infections-Therapeutics under Investigation by Universities/Institutes 14

Zika Virus Infections-Pipeline Products Glance 15

Clinical Stage Products 15

Early Stage Products 16

Zika Virus Infections-Products under Development by Companies 17

Zika Virus Infections-Products under Investigation by Universities/Institutes 20

Zika Virus Infections-Companies Involved in Therapeutics Development 21

Bharat Biotech International Ltd 21

Biken Inc 22

BioCryst Pharmaceuticals Inc 23

Biotron Ltd 24

CaroGen Corp 25

Codagenix Inc 26

Ennaid Therapeutics LLC 27

Etubics Corp 28

GeneOne Life Science, Inc. 29

GeoVax Labs Inc 30

Hawaii Biotech Inc 31

Hemispherx Biopharma Inc 32

HSRx Group 33

Humabs BioMed SA 34

Immunovaccine Inc 35

Kineta Inc 36

Mymetics Corp 37

NewLink Genetics Corp 38

Novavax Inc 39

OXIS International Inc 40

PaxVax Inc 41

Pharos Biologicals LLC 42

Plex Pharmaceuticals Inc 43

Prokarium Ltd 44

Protein Sciences Corp 45

Regeneron Pharmaceuticals Inc 46

Replikins Ltd 47

Sanofi Pasteur SA 48

Sirnaomics Inc 49

Spotlight Innovation Inc 50

Starpharma Holdings Ltd 51

Takeda Pharmaceutical Company Ltd 52

Tamir Biotechnology Inc 53

TGV-Laboratories 54

Themis Bioscience GmbH 55

Valneva SE 56

Vaxart Inc 57

VaxInnate Corp 58

VBI Vaccines Inc 59

Visterra Inc 60

VLP Therapeutics LLC 61

Zika Virus Infections-Therapeutics Assessment 62

Assessment by Monotherapy Products 62

Assessment by Target 63

Assessment by Mechanism of Action 65

Assessment by Route of Administration 67

Assessment by Molecule Type 69

Drug Profiles 71

AGS-v-Drug Profile 71

Alferon LDO-Drug Profile 72

Antibodies to Inhibit Envelope Protein for Dengue Fever and Zika Virus Infection-Drug Profile 74

astodrimer-Drug Profile 75

Drug for Zika Virus Infection-Drug Profile 79

emricasan-Drug Profile 80

galidesivir-Drug Profile 81

GLS-5700-Drug Profile 84

GOVXZM-01-Drug Profile 86

HSRx-431-Drug Profile 87

interferon alfa-n3-Drug Profile 88

KIN-1400-Drug Profile 91

Monoclonal Antibody for Zika Virus Infection-Drug Profile 93

Monoclonal Antibody for Zika Virus Infection-Drug Profile 94

mRNA-1325-Drug Profile 95

MV-4-Drug Profile 96

niclosamide-Drug Profile 97

P-MAPA-Drug Profile 98

ranpirnase-Drug Profile 100

rintatolimod-Drug Profile 103

Small Molecule to Inhibit NS2B-NS3 Protease for Dengue, Zika and West Nile Virus Infection-Drug Profile 111

Small Molecules for Infectious Disease-Drug Profile 112

Small Molecules for Zika Virus Infection-Drug Profile 113

Small Molecules for Zika Virus Infection-Drug Profile 114

Small Molecules for Zika Virus Infections-Drug Profile 115

Small Molecules for Zika Virus Infections-Drug Profile 116

Small Molecules to Inhibit Nonstructural Protein for Zika Virus Infection-Drug Profile 117

STP-602-Drug Profile 118

Synthetic Peptide for Zika Virus Infection-Drug Profile 119

Synthetic Peptides to Inhibit Matrix Protein for Zika Virus Infections-Drug Profile 120

TAK-426-Drug Profile 121

VIS-ZKV-Drug Profile 122

VLA-1601-Drug Profile 123

VRC-5283-Drug Profile 124

VRC-5288-Drug Profile 125

Zika [strain ZIKV/Hu/Chiba/S36/2016] virus vaccine-Drug Profile 127

Zika virus (bivalent, virus like particle) vaccine-Drug Profile 128

Zika virus (virus like particle) vaccine-Drug Profile 129

Zika virus (virus like particle) vaccine-Drug Profile 130

Zika virus vaccine-Drug Profile 131

Zika virus vaccine-Drug Profile 132

Zika virus vaccine-Drug Profile 133

Zika virus vaccine-Drug Profile 134

Zika virus vaccine-Drug Profile 136

Zika virus vaccine-Drug Profile 137

Zika virus vaccine-Drug Profile 138

Zika virus vaccine-Drug Profile 139

Zika virus vaccine-Drug Profile 140

Zika virus vaccine-Drug Profile 141

Zika virus vaccine-Drug Profile 142

Zika virus vaccine-Drug Profile 143

Zika virus vaccine-Drug Profile 144

Zika virus vaccine-Drug Profile 145

Zika virus vaccine-Drug Profile 146

Zika virus vaccine-Drug Profile 147

Zika virus vaccine-Drug Profile 148

Zika virus vaccine-Drug Profile 149

Zika virus vaccine-Drug Profile 150

Zika virus vaccine 1-Drug Profile 151

Zika virus vaccine 1-Drug Profile 152

Zika virus vaccine 1-Drug Profile 153

Zika virus vaccine 1-Drug Profile 154

ZIKV-117-Drug Profile 155

ZIKV-rEfl-Drug Profile 156

Zika Virus Infections-Product Development Milestones 157

Featured News & Press Releases 157

Appendix 169

Methodology 169

Coverage 169

Secondary Research 169

Primary Research 169

Expert Panel Validation 169

Contact Us 169

Disclaimer 170

List of Figures

Number of Products under Development for Zika Virus Infections, H2 2016 14

Number of Products under Development for Zika Virus Infections-Comparative Analysis, H2 2016 15

Number of Products under Development by Companies, H2 2016 16

Number of Products under Investigation by Universities/Institutes, H2 2016 19

Comparative Analysis by Clinical Stage Development, H2 2016 20

Comparative Analysis by Early Stage Products, H2 2016 21

Assessment by Monotherapy Products, H2 2016 67

Number of Products by Top 10 Targets, H2 2016 68

Number of Products by Stage and Top 10 Targets, H2 2016 68

Number of Products by Top 10 Mechanism of Actions, H2 2016 70

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 70

Number of Products by Top 10 Routes of Administration, H2 2016 72

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 72

Number of Products by Top 10 Molecule Types, H2 2016 74

Number of Products by Stage and Top 10 Molecule Types, H2 2016 74

List of Tables

Number of Products under Development for Zika Virus Infections, H2 2016 14

Number of Products under Development for Zika Virus Infections-Comparative Analysis, H2 2016 15

Number of Products under Development by Companies, H2 2016 16

Number of Products under Development by Companies, H2 2016 (Contd..1) 17

Number of Products under Development by Companies, H2 2016 (Contd..2) 18

Number of Products under Investigation by Universities/Institutes, H2 2016 19

Comparative Analysis by Clinical Stage Development, H2 2016 20

Comparative Analysis by Early Stage Development, H2 2016 21

Products under Development by Companies, H2 2016 22

Products under Development by Companies, H2 2016 (Contd..1) 23

Products under Development by Companies, H2 2016 (Contd..2) 24

Products under Investigation by Universities/Institutes, H2 2016 25

Zika Virus Infections-Pipeline by Bharat Biotech International Ltd, H2 2016 26

Zika Virus Infections-Pipeline by Biken Inc, H2 2016 27

Zika Virus Infections-Pipeline by BioCryst Pharmaceuticals Inc, H2 2016 28

Zika Virus Infections-Pipeline by Biotron Ltd, H2 2016 29

Zika Virus Infections-Pipeline by CaroGen Corp, H2 2016 30

Zika Virus Infections-Pipeline by Codagenix Inc, H2 2016 31

Zika Virus Infections-Pipeline by Ennaid Therapeutics LLC, H2 2016 32

Zika Virus Infections-Pipeline by Etubics Corp, H2 2016 33

Zika Virus Infections-Pipeline by GeneOne Life Science, Inc., H2 2016 34

Zika Virus Infections-Pipeline by GeoVax Labs Inc, H2 2016 35

Zika Virus Infections-Pipeline by Hawaii Biotech Inc, H2 2016 36

Zika Virus Infections-Pipeline by Hemispherx Biopharma Inc, H2 2016 37

Zika Virus Infections-Pipeline by HSRx Group, H2 2016 38

Zika Virus Infections-Pipeline by Humabs BioMed SA, H2 2016 39

Zika Virus Infections-Pipeline by Immunovaccine Inc, H2 2016 40

Zika Virus Infections-Pipeline by Kineta Inc, H2 2016 41

Zika Virus Infections-Pipeline by Mymetics Corp, H2 2016 42

Zika Virus Infections-Pipeline by NewLink Genetics Corp, H2 2016 43

Zika Virus Infections-Pipeline by Novavax Inc, H2 2016 44

Zika Virus Infections-Pipeline by OXIS International Inc, H2 2016 45

Zika Virus Infections-Pipeline by PaxVax Inc, H2 2016 46

Zika Virus Infections-Pipeline by Pharos Biologicals LLC, H2 2016 47

Zika Virus Infections-Pipeline by Plex Pharmaceuticals Inc, H2 2016 48

Zika Virus Infections-Pipeline by Prokarium Ltd, H2 2016 49

Zika Virus Infections-Pipeline by Protein Sciences Corp, H2 2016 50

Zika Virus Infections-Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 51

Zika Virus Infections-Pipeline by Replikins Ltd, H2 2016 52

Zika Virus Infections-Pipeline by Sanofi Pasteur SA, H2 2016 53

Zika Virus Infections-Pipeline by Sirnaomics Inc, H2 2016 54

Zika Virus Infections-Pipeline by Spotlight Innovation Inc, H2 2016 55

Zika Virus Infections-Pipeline by Starpharma Holdings Ltd, H2 2016 56

Zika Virus Infections-Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 57

Zika Virus Infections-Pipeline by Tamir Biotechnology Inc, H2 2016 58

Zika Virus Infections-Pipeline by TGV-Laboratories, H2 2016 59

Zika Virus Infections-Pipeline by Themis Bioscience GmbH, H2 2016 60

Zika Virus Infections-Pipeline by Valneva SE, H2 2016 61

Zika Virus Infections-Pipeline by Vaxart Inc, H2 2016 62

Zika Virus Infections-Pipeline by VaxInnate Corp, H2 2016 63

Zika Virus Infections-Pipeline by VBI Vaccines Inc, H2 2016 64

Zika Virus Infections-Pipeline by Visterra Inc, H2 2016 65

Zika Virus Infections-Pipeline by VLP Therapeutics LLC, H2 2016 66

Assessment by Monotherapy Products, H2 2016 67

Number of Products by Stage and Target, H2 2016 69

Number of Products by Stage and Mechanism of Action, H2 2016 71

Number of Products by Stage and Route of Administration, H2 2016 73

Number of Products by Stage and Molecule Type, H2 2016 75

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Bharat Biotech International Ltd , Biken Inc , BioCryst Pharmaceuticals Inc , Biotron Ltd , CaroGen Corp , Codagenix Inc , Ennaid Therapeutics LLC , Etubics Corp , GeneOne Life Science, Inc. , GeoVax Labs Inc , Hawaii Biotech Inc , Hemispherx Biopharma Inc , HSRx Group , Humabs BioMed SA , Immunovaccine Inc , Kineta Inc , Mymetics Corp , NewLink Genetics Corp , Novavax Inc , OXIS International Inc , PaxVax Inc , Pharos Biologicals LLC , Plex Pharmaceuticals Inc , Prokarium Ltd , Protein Sciences Corp , Regeneron Pharmaceuticals Inc , Replikins Ltd , Sanofi Pasteur SA , Sirnaomics Inc , Spotlight Innovation Inc , Starpharma Holdings Ltd , Takeda Pharmaceutical Company Ltd, Tamir Biotechnology Inc , TGV-Laboratories , Themis Bioscience GmbH , Valneva SE , Vaxart Inc , VaxInnate Corp , VBI Vaccines Inc , Visterra Inc , VLP Therapeutics LLC

Zika Virus Infections Therapeutic Products under Development, Key Players in Zika Virus Infections Therapeutics, Zika Virus Infections Pipeline Overview, Zika Virus Infections Pipeline, Zika Virus Infections Pipeline Assessment

select a license

Single User License
USD 2000 INR 129120
Site License
USD 4000 INR 258240
Corporate User License
USD 6000 INR 387360

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com